PMN:TSX; ARFXF:OTCQB

ProMIS Neurosciences Inc.

ProMIS Neurosciences is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSE’s are misfolded regions on otherwise normal proteins. In the infectious disease setting, these disease-specific epitopes represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19.

PMN:TSX ARFXF:OTCQB

View Company News

Visit Company Website

Expert Comments:

Biotech to Develop Alzheimer's Disease Vaccine Using Proprietary Peptide Antigens
(9/23/20)

ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies.

Canadian Biotech Advances Antibodies, Diagnostics Programs in Q2/20
(8/14/20)

One highlight is ProMIS Neurosciences' development of a SARS CoV-2 antibody test.

Clive Maund, CliveMaund.com

(7/14/20)

"This is a good point for ProMIS Neurosciences Inc.'s stock to start advancing again. . .the reason for us taking an interest in it here is that, given the proximity of support, we can place a fairly close stop to take us out if the support fails, which means that we have a favorable risk/reward ratio because the upside is relatively unlimited. The company is therefore rated an Immediate Buy here."

Biotech Partners to Develop, Offer Alzheimer's Disease Tests
(7/13/20)

ProMIS Neurosciences and its collaborator make their relationship official with a joint venture agreement.

Biotech Makes 'Significant Progress' Creating Highly Accurate COVID-19 Antibody Test
(6/17/20)

ProMIS Neurosciences states that the current version of the ProMIS-BCNI assay achieves 99.9% sensitivity and 99.5% specificity for SARS CoV-2, the coronavirus causing COVID-19.

Biotech Advances Accurate SARS CoV-2 Antibodies Detection Test
(5/13/20)

Testing and validation of ProMIS Neurosciences' antibody targets will be conducted over the coming weeks.

Building a Better Covid-19 Antibody Test
(5/6/20)

ProMIS is harnessing its unique technology platform to develop a more error-free antibody test.

Firm Creates Novel Intrabodies for ALS and Other Neurodegenerative Diseases
(5/4/20)

ProMIS Neurosciences reported it has generated novel intrabodies that are highly selective for misfolded forms of TAR DNA-binding protein 43 implicated in several neurologic disorders.

Cosme Ordonez, Noble Capital Markets

(4/20/20)

"ProMIS Neurosciences Inc. announced a collaboration to develop a sensitive and specific laboratory test to detect antibodies against SARS-CoV-2, the virus causing Covid-19. Given ProMIS' experience with peptide and antibody based technologies, we believe the company and its collaborators will be able to develop a specific test without cross-reactivity with other viruses in the coronavirus family. Thus far, high test specificity has been a challenge for the industry. . . In our opinion, ProMIS could potentially attract a big pharmaceutical company to sign a partnership to advance development of vectorization technology."

More Expert Comments

Cosme Ordonez, Noble Capital Markets (8/14/19) "In Q2/19, ProMIS Neurosciences Inc. identified several antibody drug candidates targeting the protein tau, which is a primary pharmaceutical target for the treatment of Alzheimer's disease. . .the company has now developed antibodies against toxic oligomers derived from two primary Alzheimer's targets, tau and amyloid beta. In addition, ProMIS' drug portfolio includes antibodies against alpha-synuclein and TDP43 proteins for the treatment of Parkinson's disease and amyotrophic lateral sclerosis, respectively."

Cosme Ordonez, Noble Capital Markets (7/23/19) "ProMIS Neurosciences Inc.'s currently deflated share price does not reflect the potential of the company's lead drug PMN310. In our opinion, its preclinical results could lure a larger company to sign a high value partnership, which could act as a positive catalyst for the shares."

Cosme Ordonez, Noble Capital Markets (5/15/19) "The progress made in ProMIS Neurosciences Inc.'s Parkinson's program was presented at the 14th International Conference on Alzheimer's and Parkinson's Diseases held in Lisbon, Portugal, from March 26 to 31, 2019. The company was able to showcase results demonstrating the selectivity of anti-alpha synuclein antibodies, which selectively bind to toxic forms of alpha synuclein while sparing the normal form of this protein present in healthy cells."

Clive Maund, CliveMaund.com (5/12/19) "ProMIS Neurosciences Inc. has done as expected and is a Buy again here. . .it is now showing signs that it is ready to advance anew, at a time when the broad market is showing signs that it is ready to bounce back after its trade deal shock."

Cosme Ordonez, Noble Capital Markets (3/21/19) "ProMIS Neurosciences Inc. is developing a novel therapeutic approach targeting a completely different molecular target [from Biogen's]. . .in light of Biogen's failure, we believe that ProMIS will emerge as a leader in the Alzheimer's area with a potentially disease modifying therapy. . .the currently deflated share price does not reflect the potential of ProMIS' lead drug and product pipeline."

	André Uddin, Mackie Research Capital (3/21/19) "ProMIS Neurosciences Inc. has identified multiple targets for neurodegenerative disorders: an alpha synuclein for Parkinson's, tau for Alzheimer's and SOD1 and TDP43 for amyotrophic lateral sclerosis; we expect the company to outlicense these targets and related candidates. A licensing deal could be forged in Q2/19 or Q3/19 for one of these drug candidates; multiple players are currently at the table."

André Uddin, Mackie Research Capital (3/15/19) "ProMIS Neurosciences Inc. is to initiate a Phase 1 study with PMN310 in both healthy subjects and prodromal/mild Alzheimer's patients (total n=8) in H2/19; results of this trial are expected in late 2020. Results of Biogen's Phase 3 ENGAGE trial with aducanumab are also expected in 2020; positive ENGAGE results could potentially enable ProMIS to piggyback on that data, enabling it to potentially outlicense PMN310."

Clive Maund, CliveMaund.com (3/10/19) "ProMIS Neurosciences Inc. is a biotech stock that is working out well for us. . .the long-term outlook for the company and its stock is excellent."

	André Uddin, Mackie Research Capital (2/27/19) "Through its platform, ProMIS Neurosciences Inc. has identified multiple targets for various central nervous system disorders: SOD1 for amyotrophic lateral sclerosis (ALS), TDP43 for ALS, alpha-synuclein for Parkinson's and tau for Alzheimer's. . .we expect the company to out-license those targets/candidates. . .we expect a licensing deal to be forged in Q2/19 or Q3/19; multiple players are currently at the table."

Cosme Ordonez, Noble Capital Markets (2/15/19) "We are initiating coverage on ProMIS Neurosciences Inc. with an Outperform rating and a $1 target price. . .we believe the company's stock is undervalued and does not reflect the significant potential of its lead drug PMN310. The signing of a high value partnership could act as a key catalyst for the stock."

	André Uddin, Mackie Research Capital (11/13/18) "ProMIS Neurosciences Inc. is looking to initiate a Phase 1 study with PMN310 in both healthy subjects and prodromal/mild Alzheimer's patients (a total of eight subjects) in H2/19. . .the company is looking to outlicense PMN310 after the Phase 1 study. . .it is looking to outlicense its anti-H-synuclein assets for Parkinson's disease."

Experts Following This Company

Clive Maund – CliveMaund.com

The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.

Investing Highlights

	Unique tech. platform creates highly selective antibodies for root cause of Alzheimer’s, ALS and Parkinson’s
	2nd generation PMN 310, anticipated to show significant advantages in efficacy & safety vs Biogen’s 1st to market aducanumab in Alzheimer’s
	Unique platform supports development of highly sensitive & specific blood test for antibodies specific for COVID-19

catalyst Calendar

Q2 2020	Potential successful serological antibody test for COVID-19 (end June 2020); expansion of current co
Q2 2020	Potential collaborations with pharma partners/patient associations forALS, Parkinson’s disease (comi
Q3 2020	Anticipated approval of Biogen’s aducanumab for AD, rolling BLA ongoing, news expected around end Q3